Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib von Cannon, Christopher P., MD, Dansky, Hayes M., MD, Davidson, Michael, MD, Gotto, Antonio M., MD, DPhil, Brinton, Eliot A., MD, Gould, A. Lawrence, PhD, Stepanavage, Michael, MS, Liu, Sherry Xueyu, MS, Shah, Sukrut, RPh, PhD, Rubino, Joseph, MBA, Gibbons, Patrice, MS, Hermanowski-Vosatka, Anne, MD, PhD, Binkowitz, Bruce, PhD, Mitchel, Yale, MD, Barter, Philip, MD, PhD

Volltext

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease von Cannon, Christopher P, Shah, Sukrut, Dansky, Hayes M, Davidson, Michael, Brinton, Eliot A, Gotto, Antonio M, Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B, Zafarino, Jennifer, Mitchel, Yale, Barter, Philip

Volltext

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S] von Davidson, Michael, Liu, Sherry Xueyu, Barter, Philip, Brinton, Eliot A., Cannon, Christopher P., Gotto, Antonio M., Leary, Elizabeth T., Shah, Sukrut, Stepanavage, Michael, Mitchel, Yale, Dansky, Hayes M.

Volltext